260 related articles for article (PubMed ID: 35008687)
1. Pros and Cons of Pharmacological Manipulation of cGMP-PDEs in the Prevention and Treatment of Breast Cancer.
Di Iorio P; Ronci M; Giuliani P; Caciagli F; Ciccarelli R; Caruso V; Beggiato S; Zuccarini M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008687
[TBL] [Abstract][Full Text] [Related]
2. Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation.
Shimizu-Albergine M; Rybalkin SD; Rybalkina IG; Feil R; Wolfsgruber W; Hofmann F; Beavo JA
J Neurosci; 2003 Jul; 23(16):6452-9. PubMed ID: 12878685
[TBL] [Abstract][Full Text] [Related]
3. Resistance to the nitric oxide/cyclic guanosine 5'-monophosphate/protein kinase G pathway in vascular smooth muscle cells from the obese Zucker rat, a classical animal model of insulin resistance: role of oxidative stress.
Russo I; Del Mese P; Doronzo G; Mattiello L; Viretto M; Bosia A; Anfossi G; Trovati M
Endocrinology; 2008 Apr; 149(4):1480-9. PubMed ID: 18079207
[TBL] [Abstract][Full Text] [Related]
4. Activation of the nitric oxide-cGMP pathway reduces phasic contractions in neonatal rat bladder strips via protein kinase G.
Artim DE; Kullmann FA; Daugherty SL; Wu HY; de Groat WC
Am J Physiol Renal Physiol; 2009 Aug; 297(2):F333-40. PubMed ID: 19493964
[TBL] [Abstract][Full Text] [Related]
5. Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes.
Castro LR; Schittl J; Fischmeister R
Circ Res; 2010 Nov; 107(10):1232-40. PubMed ID: 20847310
[TBL] [Abstract][Full Text] [Related]
6. Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension.
Mergia E; Stegbauer J
Curr Hypertens Rep; 2016 Apr; 18(5):39. PubMed ID: 27079836
[TBL] [Abstract][Full Text] [Related]
7. Cyclic GMP and cGMP-binding phosphodiesterase are required for interleukin-1-induced nitric oxide synthesis in human articular chondrocytes.
Geng Y; Zhou L; Thompson WJ; Lotz M
J Biol Chem; 1998 Oct; 273(42):27484-91. PubMed ID: 9765278
[TBL] [Abstract][Full Text] [Related]
8. The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders.
Degjoni A; Campolo F; Stefanini L; Venneri MA
J Thromb Haemost; 2022 Nov; 20(11):2465-2474. PubMed ID: 35950928
[TBL] [Abstract][Full Text] [Related]
9. Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases.
Kopra K; Sharina I; Martin E; Härmä H
Sci Rep; 2020 Oct; 10(1):17469. PubMed ID: 33060787
[TBL] [Abstract][Full Text] [Related]
10. Modulating cGMP to treat lung diseases.
Ghofrani HA; Grimminger F
Handb Exp Pharmacol; 2009; 191(191):469-83. PubMed ID: 19089341
[TBL] [Abstract][Full Text] [Related]
11. Identification of cytosolic phosphodiesterases in the erythrocyte: a possible role for PDE5.
Adderley SP; Thuet KM; Sridharan M; Bowles EA; Stephenson AH; Ellsworth ML; Sprague RS
Med Sci Monit; 2011 May; 17(5):CR241-7. PubMed ID: 21525805
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of nitric oxide-cyclic GMP signalling in CNS cells and its possible regulation by cyclic GMP.
Wykes V; Bellamy TC; Garthwaite J
J Neurochem; 2002 Oct; 83(1):37-47. PubMed ID: 12358727
[TBL] [Abstract][Full Text] [Related]
13. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G.
Tinsley HN; Gary BD; Keeton AB; Zhang W; Abadi AH; Reynolds RC; Piazza GA
Mol Cancer Ther; 2009 Dec; 8(12):3331-40. PubMed ID: 19996273
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells.
Tinsley HN; Gary BD; Keeton AB; Lu W; Li Y; Piazza GA
Cancer Prev Res (Phila); 2011 Aug; 4(8):1275-84. PubMed ID: 21505183
[TBL] [Abstract][Full Text] [Related]
15. Distinct phosphodiesterase 5A-containing compartments allow selective regulation of cGMP-dependent signalling in human arterial smooth muscle cells.
Wilson LS; Guo M; Umana MB; Maurice DH
Cell Signal; 2017 Aug; 36():204-211. PubMed ID: 28506928
[TBL] [Abstract][Full Text] [Related]
16. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
Bellamy TC; Garthwaite J
Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
[TBL] [Abstract][Full Text] [Related]
17. Mathematical Modelling of Nitric Oxide/Cyclic GMP/Cyclic AMP Signalling in Platelets.
Kleppe R; Jonassen I; Døskeland SO; Selheim F
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462984
[TBL] [Abstract][Full Text] [Related]
18. Cyclic GMP-dependent signaling in cardiac myocytes.
Takimoto E
Circ J; 2012; 76(8):1819-25. PubMed ID: 22785374
[TBL] [Abstract][Full Text] [Related]
19. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling.
Li N; Xi Y; Tinsley HN; Gurpinar E; Gary BD; Zhu B; Li Y; Chen X; Keeton AB; Abadi AH; Moyer MP; Grizzle WE; Chang WC; Clapper ML; Piazza GA
Mol Cancer Ther; 2013 Sep; 12(9):1848-59. PubMed ID: 23804703
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes.
Wang H; Kohr MJ; Traynham CJ; Ziolo MT
J Mol Cell Cardiol; 2009 Aug; 47(2):304-14. PubMed ID: 19345227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
